What is UserWise?
UserWise operates at the intersection of clinical efficacy and user-centered design, providing critical development services for the medical device industry. By focusing on human factors solutions, the company ensures that complex medical technologies are both safe and intuitive for end-users, thereby reducing clinical errors and improving patient outcomes. Their comprehensive service suite encompasses rigorous usability studies, end-to-end regulatory support, and robust quality management systems. This multidisciplinary approach allows pharmaceutical and MedTech organizations to navigate the complexities of product development while maintaining strict adherence to international safety standards. As a strategic partner, UserWise bridges the gap between technical innovation and practical clinical application, positioning itself as an essential entity in the modern healthcare ecosystem.
How much funding has UserWise raised?
UserWise has raised a total of $372K across 2 funding rounds:
Debt
$150K
Debt
$222K
Debt (2020): $150K with participation from PPP
Debt (2021): $222K led by PPP
Key Investors in UserWise
PPP
Public-Private Partnership
What's next for UserWise?
With the infusion of $222K, UserWise is well-positioned to accelerate its expansion into emerging markets and deepen its investment in proprietary usability testing methodologies. The company is expected to leverage this capital to enhance its regulatory advisory services, addressing the tightening compliance landscape for digital health and connected medical devices. By scaling its multidisciplinary team, UserWise aims to solidify its leadership in human factors engineering, potentially pursuing strategic partnerships or acquisitions that complement its existing service portfolio. The focus remains on driving user-centered innovation that meets the evolving needs of global healthcare providers, ensuring that the next generation of medical devices is defined by safety, accessibility, and superior performance.
See full UserWise company page
